Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years

被引:68
作者
Tattersfield, AE [1 ]
Town, GI
Johnell, O
Picado, C
Aubier, M
Braillon, P
Karlström, R
机构
[1] City Hosp, Div Resp Med, Nottingham NG5 1PB, England
[2] Christchurch Sch Med, Christchurch, New Zealand
[3] Univ Hosp, Malmo, Sweden
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hop Bichat Claude Bernard, F-75877 Paris, France
[6] Hop Edouard Herriot, Lyon, France
[7] AstaZeneca R&D, Lund, Sweden
关键词
bone mineral density; inhaled corticosteroids; asthma;
D O I
10.1136/thorax.56.4.272
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background-Inhaled corticosteroids are clearly beneficial for patients with asthma of moderate severity, but the risks and benefits of using them in patients with milder asthma are less clear. We have compared the change in bone mineral density over 2 years in adults with mild asthma randomised to receive an inhaled corticosteroid or non-corticosteroid treatment. Methods-Subjects with mild asthma (mean forced expiratory volume in one second (FEV1) 86% predicted, mean age 35 years, taking beta agonists only) were randomised to receive inhaled budesonide, inhaled beclomethasone dipropionate, or non-corticosteroid treatment for 2 years in a prospective randomised open study in 19 centres in France, New Zealand, Spain, and the UK. The corticosteroid dose was adjusted according to a written selfmanagement plan. The main outcome measure-change in bone mineral density after 6, 12, and 24 months-was measured "blind". Secondary outcomes included lung function, the relation between change in bone density and inhaled steroid dose and change in biochemical markers of bone metabolism. Results-Of 374 subjects randomised, 239 (64%) completed the study and were included in the analysis. The median daily doses of inhaled budesonide (n=87) and beclomethasone (n=74) were 389 mug and 499 mug, respectively. Subjects treated with an inhaled corticosteroid had better asthma control than those in the reference group (n=78). Change in bone mineral density did not differ between the three groups over the 2 years, nor did it correlate with changes in markers of bone metabolism. The mean change in bone mineral density over 2 years in the budesonide, beclomethasone dipropionate, and reference groups was 0.1%, -0.4%, and 0.4% for the lumbar spine and -0.9%, -0.9%, and -0.4% for neck of the femur. Mean daily dose of inhaled steroid was related to reduction in bone mineral density at the lumbar spine but not at the femoral neck. Conclusion-In subjects with mild asthma an inhaled corticosteroid provided better asthma control than alternative non-corticosteroid treatment with no difference in change in bone mineral density over 2 years. The relation between dose of inhaled corticosteroid and change in bone density at the lumbar spine may be due to a direct effect of inhaled corticosteroids on bone. Since inhaled steroid dose is also related inversely to lung function, an effect of asthma severity on bone density was also possible.
引用
收藏
页码:272 / 278
页数:7
相关论文
共 22 条
  • [11] HATTON MQ, 1992, THORAX, V47, P228
  • [12] HERRALA JT, 1995, AM J RESP CRIT CARE, V151, pA374
  • [13] One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density
    Hughes, JA
    Conry, BG
    Male, SM
    Eastell, R
    [J]. THORAX, 1999, 54 (03) : 223 - 229
  • [14] Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
    Juniper, EF
    Svensson, K
    O'Byrne, PM
    Barnes, PJ
    Bauer, CA
    Löfdahl, CGA
    Postma, DS
    Pauwels, RA
    Tattersfield, AE
    Ullman, A
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (05) : 1038 - 1043
  • [15] Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone
    Malo, JL
    Cartier, A
    Ghezzo, H
    Mark, S
    Brown, J
    Laviolette, M
    Bulet, LP
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (05) : 993 - 998
  • [16] Effect of inhaled formoterol and budesonide on exacerbations of asthma
    Pauwels, RA
    Lofdahl, CG
    Postma, DS
    Tattersfield, AE
    OByrne, P
    Barnes, PJ
    Ullman, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (20) : 1405 - 1411
  • [17] Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
    Pauwels, RA
    Löfdahl, CG
    Laitinen, LA
    Schouten, JP
    Postma, DS
    Pride, NB
    Ohlsson, SV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (25) : 1948 - 1953
  • [18] Pearson MG, 1997, THORAX, V52, pS1
  • [19] LUNG-VOLUMES AND FORCED VENTILATORY FLOWS - REPORT WORKING PARTY STANDARDIZATION OF LUNG-FUNCTION TESTS EUROPEAN-COMMUNITY FOR STEEL AND COAL - OFFICIAL STATEMENT OF THE EUROPEAN RESPIRATORY SOCIETY
    QUANJER, PH
    TAMMELING, GJ
    COTES, JE
    PEDERSEN, OF
    PESLIN, R
    YERNAULT, JC
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1993, 6 : 5 - 40
  • [20] CORTICOSTEROIDS AND OSTEOPOROSIS
    SMITH, R
    [J]. THORAX, 1990, 45 (08) : 573 - 578